Dr. Katz is the chief medical officer of eGenesis. Dr. Katz is an experienced transplant surgeon and a leader of clinical development in the pharmaceutical industry. He oversaw the development of therapeutics to modulate the immune system in autoimmune diseases and organ transplantation. Most recently, he was Vice President, Clinical Development at Horizon Therapeutics following its acquisition of Viela Bio, Inc. At Horizon and Viela, Dr. Katz led the clinical development of inebilizumab (depleting CD19 B cells), including the regulatory submission and approval of UPLIZNA® (inebilizumab) to treat neuromyelitis optica spectrum disorder in adults.
Prior to his tenure at Viela and Horizon, Dr. Katz served as Senior Director of Clinical Development at MedImmune Inc., where he oversaw the clinical development of three different biologics in three different autoimmune diseases. Before that, Dr. Katz served as the Senior Director of Transplantation with the Medicine Development Group at Pfizer, Inc. At Pfizer, he worked across business divisions to oversee multiple research programs with rapamycin, an anti-rejection drug, strengthening his relationships with the medical and surgical transplant community, and conducting key advisory boards. Dr. Katz participated in the planning of Phase 3 clinical trials for tofacitinib, a JAK3 inhibitor and a novel immunosuppressive drug. He was instrumental in the regulatory submission and FDA approval in 2015 of rapamycin as a treatment for lymphangioleiomyomatosis (LAM), a rare and fatal lung disease. Dr. Katz’s first position in the pharmaceutical industry was at CTI Clinical Trial and Consulting Services where he served as the VP of Medical Affairs and supported all stages of drug development and clinical trials in transplantation, immunology, and other related areas.
Before joining industry, Dr. Katz had an almost two-decade career as a transplant surgeon, including the directorship of two transplantation programs. He was director of the abdominal transplantation division at Integris Baptist Medical Center in Oklahoma City, and an associate professor of surgery and the director of the liver transplantation division at the University of Massachusetts Medical Center, Worcester, MA. In both positions Dr. Katz implemented techniques related to liver transplantation and was actively involved with policy making in organ donation and allocation.